Global Herceptin (Trastuzumab) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Herceptin (Trastuzumab) and Biosimilar market size was valued at USD 4642.6 million in 2022 and is forecast to a readjusted size of USD 6357.7 million by 2029 with a CAGR of 4.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
This report is a detailed and comprehensive analysis for global Herceptin (Trastuzumab) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Herceptin (Trastuzumab) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Herceptin (Trastuzumab) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Organon and Teva and etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Herceptin (Trastuzumab) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Herceptin (Trastuzumab) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Herceptin (Trastuzumab) and Biosimilar, with price, sales, revenue and global market share of Herceptin (Trastuzumab) and Biosimilar from 2018 to 2023.
Chapter 3, the Herceptin (Trastuzumab) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Herceptin (Trastuzumab) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Herceptin (Trastuzumab) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Herceptin (Trastuzumab) and Biosimilar.
Chapter 14 and 15, to describe Herceptin (Trastuzumab) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
This report is a detailed and comprehensive analysis for global Herceptin (Trastuzumab) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Herceptin (Trastuzumab) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Herceptin (Trastuzumab) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Herceptin (Trastuzumab) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Organon and Teva and etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Herceptin (Trastuzumab) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Brand
- Biosimilar
- Breast Cancer
- Stomach Cancer
- Roche
- Amgen
- Pfizer
- Organon
- Teva
- Viatris
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Herceptin (Trastuzumab) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Herceptin (Trastuzumab) and Biosimilar, with price, sales, revenue and global market share of Herceptin (Trastuzumab) and Biosimilar from 2018 to 2023.
Chapter 3, the Herceptin (Trastuzumab) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Herceptin (Trastuzumab) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Herceptin (Trastuzumab) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Herceptin (Trastuzumab) and Biosimilar.
Chapter 14 and 15, to describe Herceptin (Trastuzumab) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Herceptin (Trastuzumab) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Brand
1.3.3 Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Breast Cancer
1.4.3 Stomach Cancer
1.5 Global Herceptin (Trastuzumab) and Biosimilar Market Size & Forecast
1.5.1 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
2.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
2.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
2.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Organon
2.4.1 Organon Details
2.4.2 Organon Major Business
2.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
2.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Organon Recent Developments/Updates
2.5 Teva
2.5.1 Teva Details
2.5.2 Teva Major Business
2.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
2.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Teva Recent Developments/Updates
2.6 Viatris
2.6.1 Viatris Details
2.6.2 Viatris Major Business
2.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
2.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Viatris Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR BY MANUFACTURER
3.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Herceptin (Trastuzumab) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Herceptin (Trastuzumab) and Biosimilar Manufacturer Market Share in 2022
3.5 Herceptin (Trastuzumab) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Herceptin (Trastuzumab) and Biosimilar Market: Region Footprint
3.5.2 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
3.5.3 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size by Region
4.1.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.5 South America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Herceptin (Trastuzumab) and Biosimilar Market Size by Country
7.3.1 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Herceptin (Trastuzumab) and Biosimilar Market Size by Country
8.3.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Herceptin (Trastuzumab) and Biosimilar Market Size by Country
10.3.1 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Herceptin (Trastuzumab) and Biosimilar Market Drivers
12.2 Herceptin (Trastuzumab) and Biosimilar Market Restraints
12.3 Herceptin (Trastuzumab) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Herceptin (Trastuzumab) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Herceptin (Trastuzumab) and Biosimilar
13.3 Herceptin (Trastuzumab) and Biosimilar Production Process
13.4 Herceptin (Trastuzumab) and Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Herceptin (Trastuzumab) and Biosimilar Typical Distributors
14.3 Herceptin (Trastuzumab) and Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Herceptin (Trastuzumab) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Brand
1.3.3 Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Breast Cancer
1.4.3 Stomach Cancer
1.5 Global Herceptin (Trastuzumab) and Biosimilar Market Size & Forecast
1.5.1 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
2.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
2.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
2.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Organon
2.4.1 Organon Details
2.4.2 Organon Major Business
2.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
2.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Organon Recent Developments/Updates
2.5 Teva
2.5.1 Teva Details
2.5.2 Teva Major Business
2.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
2.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Teva Recent Developments/Updates
2.6 Viatris
2.6.1 Viatris Details
2.6.2 Viatris Major Business
2.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
2.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Viatris Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR BY MANUFACTURER
3.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Herceptin (Trastuzumab) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Herceptin (Trastuzumab) and Biosimilar Manufacturer Market Share in 2022
3.5 Herceptin (Trastuzumab) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Herceptin (Trastuzumab) and Biosimilar Market: Region Footprint
3.5.2 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
3.5.3 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size by Region
4.1.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.5 South America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Herceptin (Trastuzumab) and Biosimilar Market Size by Country
7.3.1 North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Herceptin (Trastuzumab) and Biosimilar Market Size by Country
8.3.1 Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Herceptin (Trastuzumab) and Biosimilar Market Size by Country
10.3.1 South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Herceptin (Trastuzumab) and Biosimilar Market Drivers
12.2 Herceptin (Trastuzumab) and Biosimilar Market Restraints
12.3 Herceptin (Trastuzumab) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Herceptin (Trastuzumab) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Herceptin (Trastuzumab) and Biosimilar
13.3 Herceptin (Trastuzumab) and Biosimilar Production Process
13.4 Herceptin (Trastuzumab) and Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Herceptin (Trastuzumab) and Biosimilar Typical Distributors
14.3 Herceptin (Trastuzumab) and Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 6. Roche Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Roche Recent Developments/Updates
Table 8. Amgen Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Major Business
Table 10. Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 11. Amgen Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amgen Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 16. Pfizer Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Organon Basic Information, Manufacturing Base and Competitors
Table 19. Organon Major Business
Table 20. Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 21. Organon Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Organon Recent Developments/Updates
Table 23. Teva Basic Information, Manufacturing Base and Competitors
Table 24. Teva Major Business
Table 25. Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 26. Teva Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Teva Recent Developments/Updates
Table 28. Viatris Basic Information, Manufacturing Base and Competitors
Table 29. Viatris Major Business
Table 30. Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 31. Viatris Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Viatris Recent Developments/Updates
Table 33. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 34. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 35. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 36. Market Position of Manufacturers in Herceptin (Trastuzumab) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 37. Head Office and Herceptin (Trastuzumab) and Biosimilar Production Site of Key Manufacturer
Table 38. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
Table 39. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
Table 40. Herceptin (Trastuzumab) and Biosimilar New Market Entrants and Barriers to Market Entry
Table 41. Herceptin (Trastuzumab) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 43. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 44. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 45. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 46. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 47. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 48. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 49. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 50. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 55. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 56. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 57. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 58. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 59. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 60. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 61. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 62. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 63. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 64. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 65. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 66. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 67. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 72. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 73. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 74. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 77. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 78. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 79. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 80. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 81. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 82. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 83. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 84. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 85. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 86. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 87. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 88. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 89. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 90. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 91. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 92. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 93. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 94. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 97. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 98. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 99. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 100. Herceptin (Trastuzumab) and Biosimilar Raw Material
Table 101. Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar Raw Materials
Table 102. Herceptin (Trastuzumab) and Biosimilar Typical Distributors
Table 103. Herceptin (Trastuzumab) and Biosimilar Typical Customers
Table 1. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 6. Roche Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Roche Recent Developments/Updates
Table 8. Amgen Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Major Business
Table 10. Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 11. Amgen Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amgen Recent Developments/Updates
Table 13. Pfizer Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer Major Business
Table 15. Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 16. Pfizer Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer Recent Developments/Updates
Table 18. Organon Basic Information, Manufacturing Base and Competitors
Table 19. Organon Major Business
Table 20. Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 21. Organon Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Organon Recent Developments/Updates
Table 23. Teva Basic Information, Manufacturing Base and Competitors
Table 24. Teva Major Business
Table 25. Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 26. Teva Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Teva Recent Developments/Updates
Table 28. Viatris Basic Information, Manufacturing Base and Competitors
Table 29. Viatris Major Business
Table 30. Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 31. Viatris Herceptin (Trastuzumab) and Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Viatris Recent Developments/Updates
Table 33. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 34. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 35. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 36. Market Position of Manufacturers in Herceptin (Trastuzumab) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 37. Head Office and Herceptin (Trastuzumab) and Biosimilar Production Site of Key Manufacturer
Table 38. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
Table 39. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
Table 40. Herceptin (Trastuzumab) and Biosimilar New Market Entrants and Barriers to Market Entry
Table 41. Herceptin (Trastuzumab) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 43. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 44. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 45. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 46. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 47. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 48. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 49. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 50. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 55. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 56. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 57. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 58. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 59. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 60. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 61. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 62. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 63. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 64. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 65. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 66. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 67. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 72. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 73. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 74. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 77. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 78. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 79. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 80. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 81. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 82. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 83. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 84. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 85. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 86. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 87. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 88. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 89. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 90. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 91. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 92. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 93. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 94. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 97. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 98. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 99. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 100. Herceptin (Trastuzumab) and Biosimilar Raw Material
Table 101. Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar Raw Materials
Table 102. Herceptin (Trastuzumab) and Biosimilar Typical Distributors
Table 103. Herceptin (Trastuzumab) and Biosimilar Typical Customers
LIST OF FIGURES
Figure 1. Herceptin (Trastuzumab) and Biosimilar Picture
Figure 2. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Brand Examples
Figure 5. Biosimilar Examples
Figure 6. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Breast Cancer Examples
Figure 9. Stomach Cancer Examples
Figure 10. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Herceptin (Trastuzumab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Herceptin (Trastuzumab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 52. China Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Herceptin (Trastuzumab) and Biosimilar Market Drivers
Figure 73. Herceptin (Trastuzumab) and Biosimilar Market Restraints
Figure 74. Herceptin (Trastuzumab) and Biosimilar Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Herceptin (Trastuzumab) and Biosimilar in 2022
Figure 77. Manufacturing Process Analysis of Herceptin (Trastuzumab) and Biosimilar
Figure 78. Herceptin (Trastuzumab) and Biosimilar Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
Figure 1. Herceptin (Trastuzumab) and Biosimilar Picture
Figure 2. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. Brand Examples
Figure 5. Biosimilar Examples
Figure 6. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Application in 2022
Figure 8. Breast Cancer Examples
Figure 9. Stomach Cancer Examples
Figure 10. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Herceptin (Trastuzumab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Herceptin (Trastuzumab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 52. China Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Herceptin (Trastuzumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Herceptin (Trastuzumab) and Biosimilar Market Drivers
Figure 73. Herceptin (Trastuzumab) and Biosimilar Market Restraints
Figure 74. Herceptin (Trastuzumab) and Biosimilar Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Herceptin (Trastuzumab) and Biosimilar in 2022
Figure 77. Manufacturing Process Analysis of Herceptin (Trastuzumab) and Biosimilar
Figure 78. Herceptin (Trastuzumab) and Biosimilar Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
